Camber – Recall of atovaquone oral suspension

- On March 14, 2023, Camber Pharmaceuticals announced a consumer-level recall of one lot of atovaquone oral suspension due to potential *Bacillus cereus* contamination in the product.
    - Other atovaquone oral suspension products made by other manufacturers that are not being recalled are available for use.
- This lot was distributed nationwide.

Product Description	NDC#	Lot# (Expiration Date)
Atovaquone oral suspension, 750 mg/5 mL, 210 mL bottle	31722-629-21	E220182 (12/2023)

- Atovaquone oral suspension is indicated for the treatment and prevention of *Pneumocystis jirovecii* pneumonia in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole.
- In the population most at risk, immunocompromised population, there is a reasonable probability that microbial contamination of atovaquone oral suspension can result in disseminated, life-threatening infections such as endocarditis and necrotizing soft tissue infections.
- Patients who are currently using the recalled atovaquone oral suspension should stop use and contact their pharmacy for a replacement. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product.
- Anyone with an existing inventory of the recalled product should stop use, distribution, and quarantine the product immediately and arrange for return.
- Contact Inmar by phone at **1-877-597-0878** or by e-mail at rxrecalls@inmar.com for questions regarding this recall.